The downregulation of p-Akt and p-STAT3 suggests that the combination treatment interferes with these signaling pathways, potentially influencing downstream targets such as SLC7A11 and inducing ferroptosis in lung cancer cells (Zhao et al., 2019; Wang J-G. This evidence concerns the gene STAT3 and lung carcinoma.